Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer.

Hayato YokotaKazuhiro SatoSho SakamotoYuji OkudaMariko AsanoMasahide TakedaKatsutoshi NakayamaMasatomo Miura

Published in: Journal of clinical pharmacy and therapeutics (2020)

Clinical outcomes of gefitinib in patients with the STAT3 rs4796793C/C genotype depended on plasma concentrations of gefitinib. In addition to information regarding EGFR mutations, the STAT3 rs4796793C >G polymorphism and gefitinib C0 may be potential predictors of clinical outcomes after beginning of gefitinib therapy.

Keyphrases

small cell lung cancer
epidermal growth factor receptor
tyrosine kinase
cell proliferation
healthcare
risk assessment
health information